RENB vs. CVAC, CNTA, SPRY, TYRA, ZNTL, IRON, PRAX, EOLS, ETNB, and NRIX
Should you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include CureVac (CVAC), Centessa Pharmaceuticals (CNTA), ARS Pharmaceuticals (SPRY), Tyra Biosciences (TYRA), Zentalis Pharmaceuticals (ZNTL), Disc Medicine (IRON), Praxis Precision Medicines (PRAX), Evolus (EOLS), 89bio (ETNB), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical preparations" industry.
Renovaro (NASDAQ:RENB) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Renovaro has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500.
Renovaro has a net margin of 0.00% compared to CureVac's net margin of -463.49%. CureVac's return on equity of -49.22% beat Renovaro's return on equity.
CureVac received 22 more outperform votes than Renovaro when rated by MarketBeat users.
CureVac has a consensus price target of $8.33, indicating a potential upside of 85.60%. Given CureVac's higher possible upside, analysts plainly believe CureVac is more favorable than Renovaro.
Renovaro has higher earnings, but lower revenue than CureVac. CureVac is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.
In the previous week, CureVac had 4 more articles in the media than Renovaro. MarketBeat recorded 4 mentions for CureVac and 0 mentions for Renovaro. CureVac's average media sentiment score of 0.35 beat Renovaro's score of 0.00 indicating that CureVac is being referred to more favorably in the news media.
71.4% of Renovaro shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 21.7% of Renovaro shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
CureVac beats Renovaro on 9 of the 15 factors compared between the two stocks.
Get Renovaro News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renovaro Competitors List
Related Companies and Tools
